Past year
All results
- All results
- Verbatim
Sep 4, 2024 · Zijlstra, et al. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial ... Heart Failure: The ARIC Study.
Jan 8, 2024 · Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES Trial. J. Am. Coll. Cardiol. 74, 1167–1176 (2019) ...
Oct 18, 2024 · Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study. Published ...
Nov 29, 2023 · ODYSSEY reported a 54% reduction in LDL-C compared with baseline after six months of alirocumab therapy; for FOURIER and evolocumab, this was 61%.8,9 Our data ...
Sep 10, 2024 · In the ODYSSEY OUTCOMES trial alirocumab was evaluated in 18,924 patients ... Alirocumab in patients with polyvascular disease and recent acute coronary syndrome.
Jun 18, 2024 · ... Alirocumab and cardiovascular outcomes after acute coronary ... patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial.
May 23, 2024 · Alirocumab and Cardiovascular Outcomes after Acute. Coronary Syndrome. The ... Coronary Disease in Statin-Treated Patients: The GLAGOV. Randomized Clinical Trial.
Sep 20, 2024 · Inclisiran trials 74 have excluded patients with HF NYHA classes II, III, and IV and patients with LVEF < 30%. Also, the CLEAR-OUTCOMES trial of bempedoic acid ...
Apr 30, 2024 · Ticagrelor reduced major adverse cardiovascular events (MACE) and increased bleeding in patients with type 2 diabetes mellitus (T2DM) and coronary artery ...
Nov 30, 2023 · Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N ... Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.